# Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS)

> **NCT04572841** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 84 (actual)

## Conditions studied

- Sjögren's Syndrome
- Sjogren's Syndrome

## Interventions

- **DRUG:** SAR441344
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04572841
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-12
- **Primary completion:** 2023-11-08
- **Final completion:** 2024-02-09
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2025-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04572841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04572841, "Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04572841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*